Innate's Lirilumab In Limbo After Phase II Combo Failure
Executive Summary
Bristol-Myers Squibb and Innate Pharma's anti-KIR monoclonal antibody lirilumab has failed to show efficacy in a combination trial with Opdivo in head and neck cancer – further development of the doublet treatment in solid tumors now seems unlikely.
You may also be interested in...
Innate Pharma's Expanded IO AstraZeneca Deal Jump-Starts US Ambitions
France's Innate Pharma gets a boost to its plans to become a fully integrated biotech by forging a long-term immuno-oncology development partnership with AstraZeneca, and the setting up of a commercialization team in the US.
Podcast: Creating A Digital Biotech Story
In this latest instalment of the In Vivo podcast Daniel Lofaso, CEO of Digital Elevator, talks about the common mistakes biotech companies make when trying to build their brand, how to connect with varied audiences and key trends the industry should keep track of in digital marketing.
AI Driving Innovation: Insights From Exscientia CEO Andrew Hopkins
Andrew Hopkins, founder and CEO of Exscientia, invented and championed an algorithmic approach to drug design and drug discovery. He talks to In Vivo about artificial intelligence in the biopharma industry today and what lies ahead.